Immunotherapy targeting PD-L1 is not yet practiced in Zambia, and the prevalence of PD-L1 expression in GC patients remains unknown, resulting in a lack of evidence to support the use of anti-PD-1/PD-L1 immunotherapy. This evidence concerns the gene CD274 and gastric cancer.